Oncology Analytics
Michael Liang oversees healthcare investments on the venture side of Baird Capital and has been with the firm since 2006. Prior to joining Baird Capital, Mike was a healthcare investor with Advent Venture Partners (London, UK) and before that served in an operating role as a Director of R&D at Cortek, a spinal orthopedics company. Mike currently serves on the Board of Directors of Apervita, AiCure, GreenLight Biosciences, Oncology Analytics, and Zurex Pharma. He was previously a board member of Veniti (sold to Boston Scientific) Interlace Medical (sold to Hologic) and a board observer of TomoTherapy (NASDAQ: TOMO). Mike received a B.S. from the University of California Berkeley in bioorganic chemistry, completed a Ph.D. in biophysical chemistry from Stanford University, and conducted a postdoctoral fellowship at Harvard University.
This person is not in the org chart
This person is not in any offices
Oncology Analytics
Oncology Analytics, Inc. provides health plans with an evidence-based, technologically driven approach to utilization management, which is purpose-built for oncology. Used by physicians to support over 2.5 million health plan members in the US and Puerto Rico, the e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy and supportive care